These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2488914)

  • 1. [In vitro evaluation of the activity and interactions of cefotaxime and its metabolite desacetylcefotaxime against strains of enterobacteria, staphylococci and Bacteroides fragilis isolated from hospital infections].
    Pitzus E
    G Ital Chemioter; 1989; 36(1-3):57-64. PubMed ID: 2488914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic activity of cefotaxime and desacetylcefotaxime against the Bacteroides fragilis group.
    Cornick NA; Gorbach SL
    Diagn Microbiol Infect Dis; 1988 Jun; 10(2):81-4. PubMed ID: 3224498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial activity of combined cefotaxime and desacetyl-cefotaxime against aerobic and anaerobic gram-negative bacilli.
    Marone P; Navarra A; Monzillo V; Traverso A
    Drugs Exp Clin Res; 1990; 16(12):629-33. PubMed ID: 2130005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of cefoxitin, cefotaxime alone, and in combination with desacetylcefotaxime against the Bacteroides species.
    Canawati HN
    Diagn Microbiol Infect Dis; 1989; 12(1):33-7. PubMed ID: 2714070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1989; 12(1):45-50. PubMed ID: 2714072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
    Wasilauskas BL
    Diagn Microbiol Infect Dis; 1989; 12(1):39-43. PubMed ID: 2714071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro synergy between cefotaxime and its main metabolite, desacetylcefotaxime].
    Kobayashi S; Arai S; Hayashi S; Sakaguchi T; Kawana R
    Jpn J Antibiot; 1988 May; 41(5):594-601. PubMed ID: 3216482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of cefotaxime and desacetylcefotaxime against pathogenic bacteria. Assessment with the serum bactericidal test.
    Reller LB
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):55S-61S. PubMed ID: 6086219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime.
    Neu HC
    Rev Infect Dis; 1982; 4 Suppl():S374-8. PubMed ID: 6294786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.
    Aldridge KE; Sanders CV; Marier RL
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):47S-53S. PubMed ID: 6086218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):21S-31S. PubMed ID: 6086215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the bactericidal activity of cefotaxime and desacetylcefotaxime alone and in combination against Bacteroides fragilis group organisms.
    Aldridge KE; Weeks LS; Stratton CW; Sanders CV
    Diagn Microbiol Infect Dis; 1989; 12(2):165-70. PubMed ID: 2752714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A reassessment of the activity of the third-generation cephalosporins against anaerobes and Staphylococcus aureus.
    Canawati HN
    Am J Surg; 1992 Oct; 164(4A Suppl):24S-27S. PubMed ID: 1443357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria.
    Devlin HR; Boskovski L
    Drugs; 1988; 35 Suppl 2():45-50. PubMed ID: 3396488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.
    Jones RN; Barry AL; Packer RR
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):37S-46S. PubMed ID: 6086217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro studies on cefotaxime and desacetylcefotaxime.
    Selwyn S; Bakhtiar M
    Drugs Exp Clin Res; 1986; 12(12):953-65. PubMed ID: 3494587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review.
    Jones RN
    Diagn Microbiol Infect Dis; 1995; 22(1-2):19-33. PubMed ID: 7587039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro action of moxalactam on hospital bacteria. Results of a multicenter survey].
    Duval J; Deforges L; Bergogne-Berezin E; Chabbert YA; Courtieu AL; Cluzel R; Dabernat H; Witchitz JL
    Sem Hop; 1983 Jun; 59(26):1949-52. PubMed ID: 6310784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs.
    Jones RN
    J Antimicrob Chemother; 1984 Sep; 14 Suppl B():39-43. PubMed ID: 6094461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.